Are target-family-privileged substructures truly privileged?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2006-02-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0502900PMID 16539387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive in silico modeling for hERG channel blockers.

  2005cited by this paper
• Computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2005cited by this paper
• Approaches to target class combinatorial library design.

  2004cited by this paper
• The different strategies for designing GPCR and kinase targeted libraries.

  2004cited by this paper
• Design of a gene family screening library targeting G-protein coupled receptors.

  2004cited by this paper
• The selection and design of GPCR ligands: from concept to the clinic.

  2004cited by this paper
• Recognition of privileged structures by G-protein coupled receptors.

  2004cited by this paper
• Ligand identification for G-protein-coupled receptors: a lead generation perspective.

  2004cited by this paper
• Performance of 3D-database molecular docking studies into homology models.

  2004cited by this paper
• The combinatorial synthesis of bicyclic privileged structures or privileged substructures.

  2003cited by this paper
• Medicinal chemistry of target family-directed masterkeys.

  2003cited by this paper
• Chemical substructures in drug discovery.

  2003cited by this paper
• An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design

  2002cited by this paper
• (R)-3-Amidinophenylalanine-Derived Inhibitors of Factor Xa with a Novel Active-Site Binding Mode

  2002cited by this paper
• The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.

  2001cited by this paper
• The design of competitive, small-molecule inhibitors of coagulation factor Xa.

  2001cited by this paper
• Privileged molecules for protein binding identified from NMR-based screening.

  2000cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures.

  1999cited by this paper
• The properties of known drugs. 1. Molecular frameworks.

  1996cited by this paper
• Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

  1988cited by this paper

• Synthesis and SAR investigation of biphenylaminoquinoline derivatives with benzyloxy substituents as promising anticancer agents

  2024cites this paper
• Challenges of Protein-Protein Docking of the Membrane Proteins.

  2024cites this paper
• The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies

  2023cites this paper
• The pyridazine heterocycle in molecular recognition and drug discovery

  2023cites this paper
• Quantitative and Qualitative Analysis of the Anti-Proliferative Potential of the Pyrazole Scaffold in the Design of Anticancer Agents

  2022cites this paper
• Solid-phase synthetic method for N-alkyl-4-alkylamino-6-arylthieno[3,2-d]pyrimidine-2-carboxamide derivatives

  2021cites this paper
• Systematic Exploration of Activity Cliffs Containing Privileged Substructures.

  2020cites this paper
• Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors

  2019cites this paper
• Clustering Bioactive Molecules in 3D Chemical Space with Unsupervised Deep Learning

  2019influential citation
• Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ.

  2019cites this paper
• Cheminformatics in the Service of GPCR Drug Discovery.

  2018cites this paper
• The impact of in silico screening in the discovery of novel and safer drug candidates.

  2017cites this paper
• In silico prediction of ROCK II inhibitors by different classification approaches

  2017cites this paper
• Privileged Substructures to Modulate Protein-Protein Interactions

  2017cites this paper
• Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.

  2017cites this paper
• A novel solid-phase synthetic method for production of N-alkyl-4-alkylamino-1-aryl-1H-pyrazolo[3,4-d]pyrimidine-6-carboxamide library

  2017cites this paper
• Synthesis and pharmacological activity of 2-(biphenyl-4-yl)imidazo[1,2-a]benzimidazoles

  2017cites this paper
• Network Variants for Analyzing Target-Ligand Interactions

  2016cites this paper
• C3-Symmetric cinchonine-squaramide as a recyclable efficient organocatalyst for tandem Michael addition–cyclisation of malononitrile and nitrovinylphenols

  2016cites this paper
• Novel Solid‐phase and Solution‐phase Synthetic Methods for Trisubstituted Thieno[3,2‐d]pyrimidine Derivatives

  2016cites this paper
• In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method

  2016cites this paper
• Lead Generation Based on Compound Collection Screening

  2016cites this paper
• A Scalable Method for Regioselective 3-Acylation of 2-Substituted Indoles under Basic Conditions.

  2015cites this paper
• Computational Fragment-Based Drug Design

  2015cites this paper
• In silico prediction of chemical toxicity on avian species using chemical category approaches.

  2015cites this paper
• Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites

  2015cites this paper
• ChemScreener: A Distributed Computing Tool for Scaffold based Virtual Screening.

  2015cites this paper
• Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds.

  2014cites this paper
• Benzimidazoles: an ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands.

  2014cites this paper
• SYNTEZA I AKTYWNOŚĆ BIOLOGICZNA NOWYCH ANALOGÓW TIOSEMIKARBAZONOWYCH CHELATORÓW ŻELAZA

  2013cites this paper
• Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families

  2013cites this paper
• Biodiversity of small molecules--a new perspective in screening set selection.

  2013cites this paper
• Fragment Informatics and Computational Fragment‐Based Drug Design: An Overview and Update

  2013cites this paper
• Scaffold Mining of Publicly Available Compound Data

  2013cites this paper
• EXPLORATION OF STRUCTURE–ACTIVITY RELATIONSHIPS (SARs) AND TRANSFER OF KEY ELEMENTS IN LEAD OPTIMIZATION

  2013cites this paper
• Microwave Assisted Synthesis of Monoazanaphthalene Scaffolds

  2013cites this paper
• 3-Substituted 2-phenyl-indoles: privileged structures for medicinal chemistry

  2013cites this paper
• Quinoline-based HIV integrase inhibitors.

  2013cites this paper
• Toward an Efficient Approach to Identify Molecular Scaffolds Possessing Selective or Promiscuous Compounds

  2013cites this paper
• On the origins of drug polypharmacology

  2013cites this paper
• Exact mechanism of action of quinine is not fully understood yet but believed to inhibit heme polymerase leading to death of malaria parasites

  2012cites this paper
• Virtual Screening Strategies in Drug Design

  2012cites this paper
• Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold.

  2012cites this paper
• Using Novel Descriptor Accounting for Ligand-Receptor Interactions To Define and Visually Explore Biologically Relevant Chemical Space

  2012cites this paper
• Generating a High‐Quality Compound Collection

  2012cites this paper
• Targeted chemical libraries

  2012cites this paper
• Virtual Screening of Chemical Space: From Generic Compound Collections to Tailored Screening Libraries

  2011cites this paper
• Chemoinformatics and Computational Chemical Biology

  2011cites this paper
• Recent trends and observations in the design of high-quality screening collections.

  2011cites this paper
• Cross-Target View to Feature Selection: Identification of Molecular Interaction Features in Ligand-Target Space

  2011cites this paper
• Combining Horizontal and Vertical Substructure Relationships in Scaffold Hierarchies for Activity Prediction

  2011cites this paper
• Virtual screening strategies in drug design - methods and applications

  2011cites this paper
• Ligand specificity, privileged substructures and protein druggability from fragment-based screening.

  2011cites this paper
• Methods for combinatorial and parallel library design.

  2011cites this paper
• Lessons Learned from Molecular Scaffold Analysis

  2011cites this paper
• Activity-Aware Clustering of High Throughput Screening Data and Elucidation of Orthogonal Structure-Activity Relationships

  2011cites this paper
• Computational medicinal chemistry in fragment-based drug discovery: what, how and when.

  2011cites this paper
• The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases

  2011cites this paper
• Redox-active nuisance screening compounds and their classification

  2011cites this paper
• Scaffold Distributions in Bioactive Molecules, Clinical Trials Compounds, and Drugs

  2010cites this paper
• High Throughput Screening Approach to Lead Discovery

  2010cites this paper
• Compound Collection Enhancement and Paradigms for High-Throughput Screening — an Update

  2010cites this paper
• Molecular Scaffolds with High Propensity to Form Multi-Target Activity Cliffs

  2010cites this paper
• Chemogenomics: Systematization of Drug Discovery

  2010cites this paper
• A structural and functional study of the second periplasmic loop P2 of MalF in the maltose transporter of Escherichia coli

  2010cites this paper
• Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families.

  2010cites this paper
• A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization

  2010cites this paper
• Strategies for the design of RNA-binding small molecules.

  2010cites this paper
• Structural and Potency Relationships between Scaffolds of Compounds Active against Human Targets

  2010cites this paper
• Fragment library design: efficiently hunting drugs in chemical space.

  2010cites this paper
• Exploring target-selectivity patterns of molecular scaffolds.

  2010cites this paper
• The discovery of antibacterial agents using diversity-oriented synthesis.

  2009cites this paper
• Recent Advances in the Application of Solution NMR Spectroscopy to Multi-Span Integral Membrane Proteins.

  2009cites this paper
• Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept

  2009cites this paper
• Assessment of complex SARs using Formal Concept Analysis of fragment combinations

  2009cites this paper
• Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy

  2009cites this paper
• Knowledge‐Based and Computational Approaches to In Vitro Safety Pharmacology

  2009cites this paper
• Molecular Formal Concept Analysis for Compound Selectivity Profiling in Biologically Annotated Databases

  2009cites this paper
• Methods for Computer‐Aided Chemical Biology. Part 4: Selectivity Searching for Ion Channel Ligands and Mapping of Molecular Fragments as Selectivity Markers

  2009cites this paper
• Computational methods for the integration of biological activity and chemical space

  2009cites this paper
• Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner

  2009cites this paper
• Topological Fragment Index for the Analysis of Molecular Substructures and Their Topological Environment in Active Compounds

  2009cites this paper
• Chemogenomic strategies to expand the bioactive chemical space.

  2009cites this paper
• Design, Selection, and Evaluation of a General Kinase‐Focused Library

  2009cites this paper
• A chemogenomic approach to drug discovery: focus on cardiovascular diseases.

  2009cites this paper
• Synthesis of Novel Angular Heterocyclic Lignans by an InCl3‐Catalyzed Friedel–Crafts‐Type Cyclization

  2008cites this paper
• Coverage and bias in chemical library design.

  2008cites this paper
• Chemical fragments as foundations for understanding target space and activity prediction.

  2008cites this paper
• The use of blue native PAGE in the evaluation of membrane protein aggregation states for crystallization.

  2008cites this paper
• The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".

  2008cites this paper
• Chemical Libraries: Screening for Biologically Active Small Molecules

  2008cites this paper
• Formal concept analysis for the identification of molecular fragment combinations specific for active and highly potent compounds.

  2008cites this paper
• A new Ligand-Based approach to virtual screening, and prolifing or large chemical libraries

  2008cites this paper
• Recent developments in fragment-based drug discovery.

  2008cites this paper
• Designing Chemical Libraries Directed to Nuclear Receptors

  2008cites this paper
• Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors.

  2008cites this paper
• Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.

  2008cites this paper
• Enhanced hit-to-lead process using bioanalogous lead evolution and chemogenomics: application in designing selective matrix metalloprotease inhibitors

  2007cites this paper
• Large compound databases for structure-activity relationships studies in drug discovery.

  2007cites this paper
• Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data

  2007cites this paper